Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All provided approval/indication claims are supported by the provided prescribing information excerpts (Indications and Usage). No contradictions were identified.
Category Scores
Accurate Statements
The FDA approval is for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) who have a bi-allelic mutation in the SMN1 gene.
Section 1 INDICATIONS AND USAGE: “indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the ... SMN1 gene.”
The FDA approval includes pediatric patients with infantile-onset SMA.
Section 1 INDICATIONS AND USAGE limits to pediatric patients <2 years with bi-allelic SMN1 mutations; Section 14 Clinical Studies describes the studied population as “infantile-onset SMA” within pediatric patients <2 years treated in the trials (Study 1/2).
Unsupported Statements
Zolgensma received FDA approval on June 28, 2019.
The provided prescribing information excerpts (Sections 1, 2, and 14) do not include an FDA approval date.
Contradictions
Important Omissions
Precise labeling phrasing regarding age cutoff (“less than 2 years of age”) vs. the broader concept of “infantile-onset SMA.”
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated pertain to indication/coverage and an approval date; no dosing, contraindications, safety warnings, or treatment instructions were asserted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Approval date (June 28, 2019) is not supported by the provided prescribing information excerpts.
Suggested Improvement
Remove or qualify the approval-date claim unless supported by label text provided (e.g., by including a label section that states approval date).